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Purpose: The in vitro study suggested that proline to serine 
polymorphism in codon 475 (C1423T) of the A Disintegrin 
and Metalloprotease with ThromboSpondin type 1 repeats-13 
(ADAMTS-13) gene is related to reduced activity of ADAMTS- 
13. In this study, the frequency of the Pro475Ser polymorphism 
in Koreans was studied and plasma ADAMTS-13 activity was 
measured to find out whether this polymorphism contributes 
to decreased ADAMTS-13 activity in Koreans. Patients and 
Methods: The frequency of the C1423T allele of the 
ADAMTS13 gene was studied along with measuring plasma 
ADAMTS-13 activity in 250 healthy Korean individuals. 
Results:  The allele frequency of C1423T polymorphism was 
4%, and the median activity of CT type was 107 (69 - 143)%, 
which was lower than in controls with the CC genotype [118 
(48 - 197)%, (p = 0.021)]. Conclusion: Therefore, the Pro475Ser 
polymorphism seems to be popular in the Korean population, 
and attenuates ADAMTS-13 plasma activity.
Key Words: ADAMTS-13, polymorphism, thrombotic thromo-
bocytopenic purpura
INTRODUCTION
ADAMTS-13 is a metalloprotease that specifically 
cleaves von Willebrand (VWF) multimer.
1,2 The 
enzyme degrades unusually large VWF (UL-VWF) 
multimers by cleaving 842Tyr-843Met peptide 
bonds in susceptible A2 domains of VWF 
monomeric subunits.
3 A deficiency of ADAMTS- 
13 activity results in an accumulation of UL-VWF 
and increased platelet adhesion to vascular walls, 
and leads to thrombotic thrombocytopenic purpura 
(TTP) either by congenital deficiency or the 
presence of inhibitory antibodies of ADAMTS-13, 
which is a syndrome characterized by micro-
angiopathic hemolytic anemia, thrombocytopenia, 
neurological disorder, renal failure, and fever.
4-6 
ADAMTS-13 was purified and its genetic structure 
was recently identified.
1,7,8 Human ADAMTS13 
g e n e  i s  c o m p o s e d  o f  2 9  e x o n s  w i t h  a  s i z e  o f  3 7
kb on chromosome 9q34.
5 ADAMTS13 is the gene 
responsible for familial TTP. Discrimination 
between congenital and acquired TTP is important 
for the therapeutic plan of acute crisis, and study 
on genetic mutation is increasingly required for 
accurate diagnosis. Moreover, growing evidence 
suggests that ADAMTS-13 is a key enzyme in a 
new pathway for the regulation of VWF and 
platelet function and a new candidate for a 
genetic modifier potentially affecting overall 
hemostatic balance and the risk of bleeding 
and/or thrombosis.
9 
Since the landmark study
5 on genetic mutation 
of ADAMTS13 as a congenital cause was carried 
out by Levy et al. in 2002, more than 50 mutations 
and at least 8 common single-nucleotide polymor-
phisms have been identified to test this 
hypothesis.
10-12 Among them, the proline (Pro) to 
serine (Ser) polymorphism in codon 475 of the 
ADAMTS13 gene (Pro475Ser), caused by a base 
substitution of C1423 to T in exon 12 (C1423T) 
which was found to impair ADAMTS-13 activity Moon Ju Jang, et al. 406
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in vitro, has been reported to be common in the 
Japanese population, and suggested that the 
importance of TTP or thrombosis-related gene in 
Japanese.
10 However, subsequent studies carried 
out in the Chinese population
13 or Caucasians
14 
did not show positive correlation of C1423T with 
thrombotic disorders. The allele frequency of 
C1423T was only 1.5% in the Chinese population, 
and the heterozygous genotype was not associated 
with an increased risk of acute ischemic stroke 
and acute myocardial infarction.
13 No Pro475Ser 
polymorphism was identified in Caucasians and 
Afro-Americans, including ischemic stroke patients.
14 
In summary, the allele frequencies of Pro475Ser 
polymorphism are rare except in the Japanese 
population, and evidence to support the role of 
Pro475Ser polymorphism as a new candidate for 
a genetic modifier potentially affecting overall 
hemostatic balance and the risk of thrombosis is 
still lacking. 
PATIENTS AND METHODS
Subjects
The study population was enrolled from January 
to February 2004 from patients who visited 
Bundang CHA Hospital's health promotion center 
for a periodic health examination. Two hundred- 
fifty healthy subjects were selected to represent a 
healthy Korean population of individuals with no 
abnormal findings on examination. They comprised 
of 135 males and 115 females. The Institutional 
Review Board of Bundang CHA hospital approved 
the research protocol and informed consent was 
obtained from all participating individuals and/or 
their guardians.
Genotyping of C1423T polymorphism
DNA was extracted from leukocytes with a 
DNA extraction kit (QIAmp blood kit, Qiagen) 
according to the manufacturer’s protocol. Two 
hundred nanograms of DNA was amplified with 
PCR by using 100 pmol each of forward primer 
(F-5’-TGA GGC CAC ACC CAC ATC TTG) and 
reverse primer (R-5’-ATG CCA GAG CCT GAA 
CCA CTT), 1.5 mM MgCl2, 0.2 M each of 
deoxynucleotide triphosphates and 1 unit of Taq 
polymerase (Takara, WI, USA) in a total volume 
of 100 μL. PCR conditions were as follows: 
denaturation at 94ºC for 5 min, followed by 35 
cycles at 94ºC for 30s, and 72ºC for 30s. The 
terminal elongation was performed at 72ºC for 5 
min, by which 365 bp product was obtained. The 
PCR products were digested with Rsa 1 restriction 
enzyme for 2 hrs at 37ºC and subjected to 
electrophoresis. Two bands of 198 and 137 bp 
indicated a homozygous wild CC type, 3 
fragments of 335, 198, and 137 bp indicated 
heterozygous CT type, and a 335 bp fragment 
indicated homozygous variant TT type. 
 
Assay of ADAMTS-13 activity
The activity of plasma ADAMTS-13 was examined 
by fluorescence resonance energy transfer assay.
15 
Each 0, 1, 2, 3, 4, 5 and 6 μL of normal plasma 
specimen was added to 100 μL of substrate 
solution (FRETS-VWF73, Peptides International, 
Louisville, KY, USA), and then each fluorescent 
degree of specimens was measured in 5-min 
intervals per hr by using a fluorescence spectro-
photometer (VICTOR3, PerkinElmer, Yokohama, 
Japan). The slope of each specimen was measured 
and the standard curve was obtained from these 
measurements. 
Since substrate solution was reacted with 4 μL 
of plasma specimen of the object, the slope of each 
fluorescent degree detected at different times was 
compared with the standard curve, and the 
activation degree of ADAMTS-13 was expressed 
in percentages. The intra-assay coefficient of 
variation (CV) was 5.3%.
Statistical analysis
The distribution of allele frequencies for the 
Pro475Ser polymorphism was examined by 
2 test 
to determine whether the observed genotype 
distributions confirm to the Hardy-Weinberg 
equilibrium expectation. Differences in ADAMTS- 
13 activity according to different genotypes were 
calculated using Mann-Whitney test. A 2-tailed p 
value of less than 0.05 was regarded as 
statistically significant. Results were expressed as 
median and range. Pro475Ser Polymorphism of ADAMTS-13 in Koreans 407
Yonsei Med J Vol. 49, No. 3, 2008
Table 1. Genotypes and Allele Frequencies of C1423T Polymorphism in a Healthy Korean Population
Genotypes Allele frequencies
CC CT TT T
Observed number (%) 230 (92.0) 20 (8.0) 0 (0.0) 0.04
Expected number 230.4 19.2 0.4 0.04

2 = 0.433, df = 1, 0.5 < p <0 . 8 .
Fig. 1. Plasma ADAMTS-13 activity according to the 
genotype of C1423T polymorphism in a healthy Korean 
population.
RESULTS
Frequency of Pro475Ser polymorphism
The median ages for the CC and CT groups 
were similar (44 and 41 yrs old, respectively). 
Male to female ratio was 125:105 for the CC group 
and 10 :10 for the CT group without gender 
difference. The genotype distributions of C1423T 
polymorphic loci did not significantly deviate 
from the Hardy-Weinberg equilibrium. The 
genotype of the C1423T polymorphism was the 
CC type of 230 people (92%), CT type of 20 (8%), 
and TT type (none). The allele and heterozygote 
frequencies of the C1423T polymorphism were 4% 
and 8% (Table 1). 
 
Plasma ADAMTS-13 activity according to C1423T 
genotypes 
We measured ADAMTS-13 activity with 219 
healthy individuals chosen from 230 people of CC 
type and 19 healthy individuals of CT type 
because 11 plasma samples of 230 CC type and 1 
p l a s m a  s a m p l e  o f  2 0  C T  t y p e  w e r e  e x h a u s t e d  
during repeated experiments. The median (range) 
ADAMTS-13 activity of the CT type was 107 (69- 
143)%, which was slightly lower than that of the 
CC type, 118 [48 - 197)% (p = 0.021)] (Fig. 1). This 
difference was not affected by the presence of 1.5 
M urea (data not shown). There was no severe 
ADAMTS-13 activity deficient case in CT 
heterozygote individuals.
 
 
DISCUSSION
The allele frequency of Pro475Ser polymor-
phism in Koreans was 4%, which is between the 
range of the Japanese (5.1%)
11  and Chinese Han 
race (1.5%).
12 Since Pro475Ser polymorphism has 
b e e n  s h o w n  t o  b e  a b s e n t  i n  C a u c a s i a n s  o r  
Afro-Americans,
13 our results suggest that the 
frequency of the C1423T allele is different among 
races (Table 2) and higher in Koreans and 
Japanese than other races.
In the present study, we confirmed that 
Pro475Ser polymorphism contributes to decreased 
ADAMTS-13 activity and demonstrated mild 
decrease of plasma ADAMTS-13 activity in 
individuals with Pro475Ser polymorphism. This is 
the first demonstration of decreased activity of 
ADAMTS-1 Pro475Ser polymorphism in human 
samples, and the result is consistent with that by 
Kokame et al.,
10 who demonstrated decreased 
ADAMTS-13 activity in the media of C1423T 
mutant transfected HeLa cells. 
Severe deficiency of ADAMTS-13 activity less 
than 5% is specific for TTP.
16 A l t h o u g h  w e  c o n -
firmed that Pro475Ser polymorphism contributed 
to decreased ADAMTS-13 activity, the clinical 
implication of only 11% difference seemed to be 
questionable because there was no severe Moon Ju Jang, et al. 408
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Table 2. Genotype and Allele Frequencies of C1423T Polymorphism in Different Populations
Population
Tested subjects 
(n)
Genotypes Allele frequencies
References
CC CT TT C T
Japanese 364 328 35 1 0.949 0.051 Kokame et al.
14
Chinese 400  388 12 0 0.985 0.015 Gao et al.
15
Caucasian 250 250  0 0 1.000 0.000 Boners et al.
16
Korean 250 230 20 0 0.960 0.040 Present study
ADAMTS-13 deficient case in all heterozygotes of 
the C1423T allele examined. Therefore, this 
substitution is not likely to be clinically relevant 
to develop TTP or thrombotic disorders because 
the decrease in the activity is minimal. Further 
studies are required to clarify whether the C1423T 
substitution may act synergistically with other 
ADAMTS13 substitution or modifiers to develop 
TTP or other thrombotic disorders in the Korean 
population. 
In conclusion, the allele frequency of C1423T 
polymorphism in Koreans was 4%. The ADAMTS- 
13 Pro475Ser polymorphism is not a major 
determinant to develop thrombotic thromo-
bocytopenic purpura or thrombotic disease in the 
Korean population because its contribution to 
decreased ADAMTS-13 activity is minimal.
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